Early price reductions follow national agreement on affordability After a recent agreement with the Trump administration to broaden access to obesity and chronic-disease medicines, while also decreasing direct-to-patient prices in 2026, Novo Nordisk is delivering those reduced prices to consumers several months ahead of schedule
Key advances In the SURMOUNT-1 trial for obesity, adults with overweight or obesity without type 2 diabetes mellitus achieved placebo-subtracted weight loss of up to 20% after 72 weeks of the GLP1GIP receptor co-agonist tirzepatide, with a similar safety profile to high-dose semaglutide 5
There is no required washout period between stopping phentermine and starting a GLP-1, though your physician may want to confirm that cardiovascular parameters (heart rate, blood pressure) have returned to baseline before initiating new treatment
As a result, there was a significant reduction in primary endpoints across all studies (CV death, nonfatal MI and nonfatal stroke)
1 luglio 2019 [citato 5 giugno 2024];206:23242